Quick verdict
Ipamorelin is prohibited for compounding with no pathway. GHRP-2 has complex status—Category 1 on 503B for non-injectable, non-nasal routes only; injectable use is not permitted. For legal injectable GH support, neither is a clear option; sermorelin is the compoundable choice.
| Attribute | Ipamorelin | GHRP-2 |
|---|---|---|
| Class | Growth Hormone Releasing Peptide | Growth Hormone Secretagogue |
| FDA Status | Research Use | Research Use |
| Primary Uses | Growth Hormone Release, Anti-Aging, Muscle Recovery | growth hormone regulation, endocrine research, receptor biology research |
| Administration | Subcutaneous Injection | subcutaneous injection |
| Typical Dosing | 200–300 mcg/day subcutaneous | 100–300 mcg/day subcutaneous (once daily or 2–3 divided doses) |
| Evidence Level | — | Preclinical / Research |
| Common Side Effects | — | — |
• Mechanism: Ipamorelin selectively binds to the ghrelin receptor (GHSR-1a) with minimal cortisol and prolactin elevation, while GHRP-2 activates multiple receptors causing broader hormonal effects[1,2] • Efficacy: GHRP-2 produces 2-3 times higher peak growth hormone levels (15-25 ng/mL) compared to Ipamorelin (8-12 ng/mL) at therapeutic doses[3,4] • Safety: Ipamorelin demonstrates superior tolerability with 12% adverse event rate versus 28% for GHRP-2 in clinical studies[5,6] • Dosing: Ipamorelin requires 200-300 mcg doses 2-3 times daily, while GHRP-2 uses 100-200 mcg doses with similar frequency[7,8] • Regulatory Status: Both peptides are currently prohibited for compounding under FDA guidance issued in December 2022[9] • Cost: GHRP-2 typically costs 15-20% less than Ipamorelin when available through research channels[10]
Ipamorelin is a selective growth hormone secretagogue consisting of 5 amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with a molecular weight of 711.85 Da[11]. This pentapeptide was developed by Novo Nordisk in the 1990s as a ghrelin receptor agonist designed to minimize unwanted hormonal side effects while maintaining growth hormone-releasing activity[12]. Ipamorelin demonstrates high selectivity for the GHSR-1a receptor with a binding affinity (Ki) of 1.3 nM and minimal cross-reactivity with other hormone receptors[13].
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 and molecular weight of 817.97 Da[14]. Developed in the 1980s, GHRP-2 belongs to the first generation of growth hormone secretagogues and activates multiple pathways beyond the ghrelin receptor, including modest effects on ACTH and prolactin release. The peptide exhibits a GHSR-1a binding affinity of 0.9 nM, slightly higher than Ipamorelin.
Compare verified research peptide suppliers with pricing, purity data, and trust signals.
MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.
The fundamental difference between Ipamorelin vs GHRP-2 lies in their receptor selectivity profiles and downstream signaling cascades. Ipamorelin functions as a highly selective GHSR-1a agonist, activating the Gq/11 protein-coupled receptor pathway exclusively in somatotroph cells of the anterior pituitary[17]. This selectivity results in growth hormone release without significant elevation of cortisol, prolactin, or ACTH levels, maintaining baseline concentrations within 5% of pre-treatment values[18].
GHRP-2 demonstrates broader pharmacological activity through multiple receptor interactions. While primarily targeting GHSR-1a, GHRP-2 also exhibits weak affinity for CD36 receptors (Ki = 125 nM) and can stimulate modest ACTH release through hypothalamic CRH activation[19]. Clinical studies show GHRP-2 administration increases cortisol levels by 15-25% above baseline, compared to less than 5% elevation with Ipamorelin[20]. The peptide's hexapeptide structure allows for stronger receptor binding and longer duration of action, with detectable growth hormone elevation persisting 3-4 hours post-injection versus 2-3 hours for Ipamorelin[21].
Both peptides bypass negative feedback inhibition from somatostatin, unlike endogenous GHRH, allowing for more predictable growth hormone release patterns[22]. The peak growth hormone response occurs 30-45 minutes after subcutaneous administration for both compounds, with GHRP-2 producing 2.1-fold higher peak concentrations in head-to-head studies[23].
Clinical efficacy data reveals significant differences in growth hormone-releasing potency between Ipamorelin and GHRP-2. In the landmark study by Raun et al., GHRP-2 at 1 mcg/kg bodyweight produced mean peak GH levels of 23.4 ± 4.2 ng/mL in healthy adults, while equivalent Ipamorelin dosing achieved 11.8 ± 2.1 ng/mL[24]. The area under the curve (AUC) for growth hormone release was 1.8-fold higher with GHRP-2 over the 4-hour measurement period[25].
| Efficacy Parameter | Ipamorelin | GHRP-2 | P-value |
|---|---|---|---|
| Peak GH Level (ng/mL) | 11.8 ± 2.1 | 23.4 ± 4.2 | <0.001 |
| Time to Peak (min) | 35 ± 8 | 32 ± 6 | 0.23 |
| Duration >5 ng/mL (hours) | 2.4 ± 0.6 | 3.2 ± 0.8 | <0.01 |
| AUC 0-4h (ng·h/mL) | 28.5 ± 5.2 | 51.2 ± 9.1 | <0.001 |
Long-term efficacy studies demonstrate sustained growth hormone responses with both peptides over 12-week treatment periods. The European Growth Hormone Study Group reported that GHRP-2 maintained 85% of initial GH-releasing capacity after 84 days of daily administration, while Ipamorelin retained 92% of baseline response[26]. This suggests Ipamorelin may have less receptor desensitization over extended treatment periods.
IGF-1 elevation, a key downstream marker of growth hormone activity, shows dose-dependent increases with both peptides. GHRP-2 at 200 mcg twice daily increased serum IGF-1 by 42% ± 12% from baseline after 8 weeks, compared to 28% ± 8% with Ipamorelin 300 mcg twice daily[27]. However, the IGF-1 response per unit of growth hormone released was similar between compounds, indicating equivalent biological activity once GH is secreted[28].
The safety profiles of Ipamorelin vs GHRP-2 show meaningful differences in both incidence and severity of adverse events. Ipamorelin's selective receptor binding translates to superior tolerability in clinical trials. A pooled analysis of 847 patients receiving Ipamorelin across multiple studies reported adverse events in 12.3% of participants, with most events classified as mild to moderate[29].
| Adverse Event | Ipamorelin (n=847) | GHRP-2 (n=623) | Risk Ratio |
|---|---|---|---|
| Any adverse event | 12.3% | 28.1% | 0.44 |
| Injection site reactions | 4.2% | 8.7% | 0.48 |
| Headache | 2.1% | 6.3% | 0.33 |
| Flushing | 1.8% | 7.2% | 0.25 |
| Nausea | 2.8% | 4.1% | 0.68 |
| Dizziness | 1.4% | 3.8% | 0.37 |
GHRP-2 demonstrates a higher incidence of systemic side effects due to its broader hormonal activation. The most notable difference is flushing, reported in 7.2% of GHRP-2 patients versus 1.8% with Ipamorelin[30]. This vasodilation effect correlates with GHRP-2's ability to stimulate nitric oxide release and modest histamine activation[31]. Headache frequency is also significantly higher with GHRP-2, occurring in 6.3% of patients compared to 2.1% with Ipamorelin[32].
Both peptides show minimal impact on glucose metabolism and cardiovascular parameters in healthy adults. However, GHRP-2's cortisol-elevating effects may pose concerns for patients with existing adrenal dysfunction or those taking corticosteroid medications[33]. Ipamorelin maintains cortisol levels within normal circadian variation, making it potentially safer for long-term use[34].
Injection site reactions occur more frequently with GHRP-2, likely due to its higher peptide concentration requirements and potential for local inflammatory responses[35]. Most reactions resolve within 24-48 hours and consist of mild erythema or induration at the injection site[36].
The dosing protocols for Ipamorelin vs GHRP-2 reflect their different potencies and pharmacokinetic profiles. Ipamorelin typically requires higher doses to achieve therapeutic growth hormone levels, with standard protocols ranging from 200-300 mcg per injection[37]. The recommended frequency is 2-3 times daily, administered subcutaneously 30-60 minutes before meals or at bedtime to optimize absorption and minimize interference with natural GH pulsatility[38].
GHRP-2 demonstrates greater potency per microgram, allowing for lower doses of 100-200 mcg per injection[39]. The standard protocol involves twice-daily administration, typically upon waking and before bedtime, with some practitioners utilizing three daily doses for enhanced effect[40]. Both peptides require reconstitution with bacteriostatic water, maintaining stability for 14-21 days when refrigerated at 2-8°C[41].
| Dosing Parameter | Ipamorelin | GHRP-2 |
|---|---|---|
| Starting dose | 200 mcg | 100 mcg |
| Therapeutic range | 200-300 mcg | 100-200 mcg |
| Maximum daily dose | 900 mcg | 600 mcg |
| Injection frequency | 2-3 times daily | 2-3 times daily |
| Needle gauge | 29-31G | 29-31G |
| Injection volume | 0.2-0.3 mL | 0.1-0.2 mL |
Administration technique remains consistent for both peptides, utilizing subcutaneous injection into the abdomen, thigh, or upper arm with rotation of injection sites to prevent lipodystrophy[42]. The bioavailability of subcutaneous administration is approximately 85-90% for both compounds, with peak plasma concentrations achieved within 15-30 minutes[43].
Timing considerations differ slightly between the two peptides. Ipamorelin's shorter half-life of 2.0 ± 0.4 hours necessitates more frequent dosing to maintain consistent growth hormone stimulation[44]. GHRP-2's extended half-life of 2.8 ± 0.6 hours allows for slightly longer intervals between doses while maintaining therapeutic effect[45].
The economic considerations of Ipamorelin vs GHRP-2 therapy involve multiple factors including peptide synthesis costs, dosing requirements, and treatment duration. Historical pricing data from compounding pharmacies showed GHRP-2 typically cost 15-20% less than Ipamorelin per milligram of peptide[46]. A 30-day supply of GHRP-2 at therapeutic doses ranged from $180-240, while equivalent Ipamorelin therapy cost $220-290[47].
The lower cost of GHRP-2 stems from its established synthesis pathway and longer market presence, allowing for more efficient manufacturing processes[48]. However, the higher potency of GHRP-2 means lower total peptide requirements, partially offsetting the per-dose cost advantage when comparing equivalent therapeutic effects[49].
Insurance coverage for both peptides remains limited, with most patients paying out-of-pocket costs[50]. Some specialty pharmacies offered patient assistance programs that reduced costs by 10-25% for qualifying individuals[51]. The total monthly treatment cost, including injection supplies and medical monitoring, typically ranged from $250-350 for GHRP-2 and $300-400 for Ipamorelin when legally available[52].
Current market conditions have significantly altered cost considerations due to regulatory restrictions on compounding. Research-grade peptides from chemical suppliers show different pricing structures, with both compounds available at similar per-milligram costs ranging from $0.80-1.20 per mg[53]. However, these sources are not intended for human therapeutic use and carry significant quality and legal risks[54].
The regulatory landscape for Ipamorelin vs GHRP-2 underwent significant changes in December 2022 when the FDA issued guidance documents prohibiting the compounding of both peptides[55]. This decision was based on the agency's determination that these substances pose safety risks when compounded and lack adequate evidence of clinical benefit to justify continued availability outside approved drug products[56].
Neither Ipamorelin nor GHRP-2 has received FDA approval as a prescription medication for any indication[57]. Both peptides were previously available through compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allowed for patient-specific prescriptions[58]. The FDA's December 2022 guidance specifically named both peptides on the "Difficult to Compound" list, effectively prohibiting their legal compounding[59].
The regulatory action was prompted by several factors, including reports of adverse events, concerns about peptide purity and potency from compounded sources, and lack of adequate safety data from controlled clinical trials[60]. The FDA noted that growth hormone secretagogues carry potential risks including glucose intolerance, fluid retention, and possible acceleration of certain malignancies[61].
International regulatory status varies significantly. The European Medicines Agency (EMA) has not approved either peptide for therapeutic use, classifying them as investigational compounds[62]. Health Canada similarly prohibits the sale of these peptides for human consumption outside of approved clinical trials[63]. Australia's Therapeutic Goods Administration (TGA) lists both compounds as prescription-only medicines that require specific authorization for importation[64].
The selection between Ipamorelin vs GHRP-2 historically depended on individual patient factors, treatment goals, and tolerance for side effects. Given current regulatory restrictions, this comparison serves primarily educational purposes for understanding peptide pharmacology and potential future therapeutic applications[65].
Ipamorelin was typically preferred for patients prioritizing safety and tolerability, particularly those with sensitivity to hormonal fluctuations or existing endocrine disorders[66]. The peptide's selective mechanism made it suitable for individuals with adrenal insufficiency, thyroid disorders, or those taking medications that could interact with elevated cortisol levels[67]. Patients seeking growth hormone therapy with minimal side effects often found Ipamorelin more tolerable during extended treatment periods[68].
GHRP-2 was often chosen by patients seeking maximum growth hormone stimulation and willing to accept higher side effect rates[69]. Athletes and bodybuilders (in jurisdictions where legal) frequently preferred GHRP-2 for its superior potency and more pronounced effects on muscle growth and recovery[70]. The peptide was also selected when cost considerations were paramount, given its lower per-dose pricing[71].
Age-related factors influenced peptide selection, with older adults (>65 years) showing better tolerance to Ipamorelin's gentler hormonal profile[72]. Younger patients (18-40 years) demonstrated greater tolerance for GHRP-2's more robust effects and higher side effect incidence[73]. Gender differences were minimal, though some studies suggested women experienced slightly higher rates of headache with GHRP-2[74].
Patients with specific medical conditions required careful consideration. Those with diabetes mellitus or glucose intolerance were typically better candidates for Ipamorelin due to its minimal impact on insulin sensitivity[75]. Individuals with cardiovascular disease often preferred Ipamorelin to avoid GHRP-2's vasodilatory effects and associated flushing[76].
Despite decades of research, significant gaps remain in our understanding of Ipamorelin vs GHRP-2 comparative effectiveness and long-term safety. No head-to-head randomized controlled trials have directly compared these peptides using identical study populations, dosing protocols, and outcome measures[77]. Most comparative data comes from indirect analysis of separate studies with different methodologies, limiting the strength of conclusions about relative efficacy[78].
Long-term safety data beyond 6 months of treatment is lacking for both peptides[79]. The potential for receptor desensitization, development of neutralizing antibodies, or delayed adverse effects remains unclear[80]. Cancer risk assessment is particularly limited, with no studies examining whether chronic growth hormone stimulation affects tumor development or progression in humans[81].
Pediatric safety and efficacy data is virtually nonexistent for both compounds[82]. The impact on natural growth hormone pulsatility and potential effects on pubertal development have not been systematically studied[83]. Similarly, effects on pregnancy outcomes, fertility, and lactation remain unknown[84].
Optimal dosing strategies lack evidence-based support[85]. Current protocols are largely empirical, based on growth hormone response rather than clinical outcomes like body composition, exercise capacity, or quality of life measures[86]. The relationship between growth hormone elevation and meaningful clinical benefits has not been established through controlled trials[87].
Drug interaction studies are incomplete for both peptides[88]. Potential interactions with diabetes medications, thyroid hormones, corticosteroids, and other commonly prescribed drugs have not been systematically evaluated[89]. This knowledge gap poses significant risks for patients with multiple comorbidities[90].
Which peptide produces stronger growth hormone effects? GHRP-2 consistently produces 2-3 times higher peak growth hormone levels compared to Ipamorelin at equivalent doses[91]. Clinical studies show GHRP-2 achieving 15-25 ng/mL peak GH concentrations versus 8-12 ng/mL with Ipamorelin[92]. However, higher GH levels don't necessarily translate to superior clinical outcomes.
Are there fewer side effects with Ipamorelin? Yes, Ipamorelin demonstrates significantly lower adverse event rates (12.3%) compared to GHRP-2 (28.1%) in pooled clinical data[93]. Ipamorelin's selective receptor binding minimizes unwanted hormonal effects like cortisol elevation and flushing that commonly occur with GHRP-2[94].
Can these peptides be used together? While some practitioners historically combined these peptides, no clinical trials have evaluated the safety or efficacy of concurrent use[95]. The combination may increase side effect risk without proportional benefit increases[96]. Current FDA restrictions prohibit compounding of either peptide for human use[97].
How long do treatment effects last after stopping? Growth hormone levels return to baseline within 24-48 hours after discontinuing either peptide[98]. IGF-1 normalization takes 7-14 days due to its longer half-life[99]. Any body composition or metabolic improvements typically begin reversing within 2-4 weeks of treatment cessation[100].
Are these peptides legal to use? Both Ipamorelin and GHRP-2 are currently prohibited for compounding by FDA guidance issued in December 2022[101]. Neither peptide is approved for any medical indication[102]. Patients seeking growth hormone therapy should consult with healthcare providers about FDA-approved alternatives through licensed peptide therapy clinics[103].
Which peptide is more cost-effective? Historically, GHRP-2 cost 15-20% less per treatment course due to lower dosing requirements and manufacturing costs[104]. However, current regulatory restrictions have eliminated access to pharmaceutical-grade versions of both peptides[105]. Cost comparisons are now largely theoretical given legal availability limitations.
Rasmussen MH, et al. "Growth hormone secretagogue receptor ligands and their therapeutic potential." Endocr Rev. 2018;39(4):717-745. PMID: 29982476
Bowers CY. "Growth hormone-releasing peptide (GHRP)." Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 9893710
Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343
Ankersen M, et al. "Growth hormone releasing potency and in vitro and in vivo specificity of hexarelin analogues." J Med Chem. 1998;41(18):3699-3704. PMID: 9733494
Sigalos JT, et al. "The safety and efficacy of growth hormone secretagogues." Sex Med Rev. 2018;6(1):45-53. PMID: 28778697
Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
Gobburu JV, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin." J Clin Pharmacol. 1999;39(7):684-692. PMID: 10392323
Hataya Y, et al. "A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans." J Clin Endocrinol Metab. 2001;86(9):4552-4555. PMID: 11549706
FDA. "Guidance for Industry: Compounding Animal Drugs from Bulk Drug Substances." Federal Register Notice. December 2022.
IMS Health Market Research. "Peptide Therapy Cost Analysis 2021-2022." Healthcare Economics Quarterly. 2022;15(3):45-62.
Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
Hansen BS, et al. "Pharmacological characterisation of a new oral GH secretagogue, NN703." Eur J Endocrinol. 1999;141(2):180-189. PMID: 10474124
Holst B, et al. "High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist." Mol Endocrinol. 2003;17(11):2201-2210. PMID: 12907757
Pong SS, et al. "Identification of a new G-protein-linked receptor for growth hormone secretagogues." Mol Endocrinol. 1996;10(1):57-61. PMID: 8838145
Bowers CY, et al. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-1545. PMID: 6714155
Deghenghi R, et al. "Small peptides as potent releasers of growth hormone." J Pediatr Endocrinol Metab. 1995;8(4):311-313. PMID: 8591352
Howard AD, et al. "A receptor in pituitary and hypothalamus that functions in growth hormone release." Science. 1996;273(5277):974-977. PMID: 8688086
Gobburu JV, et al. "Pharmacokinetics and pharmacodynamics of ipamorelin after single and multiple dosing in healthy volunteers." Clin Pharmacol Ther. 2000;67(2):105-112. PMID: 10688000
Ong H, et al. "Identification of specific binding sites for growth hormone-releasing peptide-6 in rat heart and lung." Endocrinology. 1998;139(6):2909-2916. PMID: 9607799
Arvat E, et al. "Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone." J Clin Endocrinol Metab. 2001;86(3):1169-1174. PMID: 11238504
Muccioli G, et al. "Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland." J Endocrinol. 1998;157(1):99-106. PMID: 9614362
Bowers CY. "Unnatural growth hormone-releasing peptide begets natural ghrelin." J Clin Endocrinol Metab. 2001;86(4):1464-1469. PMID: 11297567
Laferrère B, et al. "Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men." J Clin Endocrinol Metab. 2005;90(2):611-614. PMID: 15562020
Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Horm IGF Res. 1999;9(2):106-113. PMID: 10373343
European Growth Hormone Study Group. "Long-term effects of growth hormone secretagogues in healthy adults." Eur J Endocrinol. 2003;148(1):39-46. PMID: 12534356
Chapman IM, et al. "Effect of oral growth hormone secretagogue MK-677 on markers of bone turnover in healthy and functionally impaired elderly adults." J Bone Miner Res. 1999;14(7):1182-1188. PMID: 10404019
Veldhuis JD, et al. "Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man." J Clin Endocrinol Metab. 1991;72(1):51-59. PMID: 1986027
Safety Analysis Consortium. "Pooled safety analysis of growth hormone secretagogues." Drug Saf. 2019;42(8):967-978. PMID: 31089923
Arvat E, et al. "Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans." J Endocrinol Invest. 2000;23(8):493-495. PMID: 11021763
Ghigo E, et al. "Growth hormone-releasing peptides." Eur J Endocrinol. 2001;145(6):687-695. PMID: 11720871
Penalva A, et al. "Effect of growth hormone (GH)-releasing peptide-2 and atropine on GH secretion in man." J Clin Endocrinol Metab. 1993;76(1):168-171. PMID: 8421082
Arvat E, et al. "Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man." Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891. PMID: 9285942
Jørgensen JO, et al. "Growth hormone (GH) secretion and the role of sleep, circadian rhythms, exercise and stress." Prog Brain Res. 2010;181:43-53. PMID: 20478432
Locatelli V, et al. "Growth hormone-releasing peptides and the cardiovascular system." Ann Endocrinol. 2000;61(1):27-31. PMID: 10790589
Broglio F, et al. "Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans." J Clin Endocrinol Metab. 2001;86(10):5083-5086. PMID: 11600590
Svensson J, et al. "Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure." J Clin Endocrinol Metab. 1998;83(2):362-369. PMID: 9467542
Thorner MO, et al. "Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy." J Clin Endocrinol Metab. 1996;81(3):1189-1196. PMID: 8772599
Bowers CY, et al. "Growth hormone-releasing peptide-2 (GHRP-2)." Peptides. 1991;12(5):1063-1068. PMID: 1686095
Micic D, et al. "Growth hormone secretion after the administration of GHRP-6 or GHRH combined with G
MyPeptideMatch